{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T06:38:03Z","timestamp":1763707083307,"version":"3.45.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s13555-025-01571-3","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T14:15:02Z","timestamp":1761315302000},"page":"3745-3756","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Gliptin-Induced Bullous Pemphigoid: Are Statins and Angiotensin Receptor Blockers the Cause?"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5726-0696","authenticated-orcid":false,"given":"Burcu","family":"Beksac","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3372-4342","authenticated-orcid":false,"given":"M. Kaan","family":"Temirkaynak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0881-4485","authenticated-orcid":false,"given":"Sheyda","family":"Gharehdaghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0545-8517","authenticated-orcid":false,"given":"Evren","family":"Atesci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0173-1054","authenticated-orcid":false,"given":"Gozde","family":"Kubat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5981-4856","authenticated-orcid":false,"given":"Ozlem","family":"Erdem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7614-3102","authenticated-orcid":false,"given":"Nilsel","family":"Ilter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8768-231X","authenticated-orcid":false,"given":"Esra","family":"Adisen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,24]]},"reference":[{"issue":"4","key":"1571_CR1","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s00403-014-1531-1","volume":"307","author":"E Alpsoy","year":"2015","unstructured":"Alpsoy E, Akman-Karakas A, Uzun S. Geographic variations in epidemiology of two autoimmune bullous diseases: pemphigus and bullous pemphigoid. Arch Dermatol Res. 2015;307(4):291\u20138.","journal-title":"Arch Dermatol Res"},{"issue":"7662","key":"1571_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.a180","volume":"337","author":"SM Langan","year":"2008","unstructured":"Langan SM, Smeeth L, Hubbard R, Fleming KM, Smith CJ, West J. Bullous pemphigoid and pemphigus vulgaris\u2013incidence and mortality in the UK: population based cohort study. BMJ. 2008;337(7662):a180.","journal-title":"BMJ"},{"issue":"3","key":"1571_CR3","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1046\/j.1365-2133.2002.04919.x","volume":"147","author":"SN Wong","year":"2002","unstructured":"Wong SN, Chua SH. Spectrum of subepidermal immunobullous disorders seen at the National Skin Centre, Singapore: a 2-year review. Br J Dermatol. 2002;147(3):476\u201380.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1571_CR4","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/1523-1747.ep12616580","volume":"99","author":"GJ Giudice","year":"1992","unstructured":"Giudice GJ, Emery DJ, Diaz LA. Cloning and primary structural analysis of the bullous pemphigoid autoantigen BP180. J Invest Dermatol. 1992;99(3):243\u201350.","journal-title":"J Invest Dermatol"},{"issue":"5","key":"1571_CR5","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.autrev.2017.03.010","volume":"16","author":"IS Bagci","year":"2017","unstructured":"Bagci IS, Horvath ON, Ruzicka T, Sardy M. Bullous pemphigoid. Autoimmun Rev. 2017;16(5):445\u201355.","journal-title":"Autoimmun Rev"},{"issue":"6","key":"1571_CR6","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s40257-021-00625-4","volume":"22","author":"PM Jedlowski","year":"2021","unstructured":"Jedlowski PM, Jedlowski MF, Fazel MT. DPP-4 inhibitors and increased reporting odds of bullous pemphigoid: a pharmacovigilance study of the FDA adverse event reporting system (FAERS) from 2006 to 2020. Am J Clin Dermatol. 2021;22(6):891\u2013900.","journal-title":"Am J Clin Dermatol"},{"issue":"10","key":"1571_CR7","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1001\/jamadermatol.2020.2158","volume":"156","author":"H Lee","year":"2020","unstructured":"Lee H, Chung HJ, Pawar A, Patorno E, Kim DH. Evaluation of risk of bullous pemphigoid with initiation of dipeptidyl peptidase-4 inhibitor vs second-generation sulfonylurea. JAMA Dermatol. 2020;156(10):1107\u201314.","journal-title":"JAMA Dermatol"},{"issue":"8","key":"1571_CR8","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.2337\/dc19-0409","volume":"42","author":"A Douros","year":"2019","unstructured":"Douros A, Rouette J, Yin H, Yu OHY, Filion KB, Azoulay L. Dipeptidyl peptidase 4 inhibitors and the risk of bullous pemphigoid among patients with type\u00a02 diabetes. Diabetes Care. 2019;42(8):1496\u2013503.","journal-title":"Diabetes Care"},{"issue":"3","key":"1571_CR9","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1007\/s12020-020-02272-x","volume":"69","author":"GA Silverii","year":"2020","unstructured":"Silverii GA, Dicembrini I, Nreu B, Montereggi C, Mannucci E, Monami M. Bullous pemphigoid and dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized controlled trials. Endocrine. 2020;69(3):504\u20137.","journal-title":"Endocrine"},{"issue":"9548","key":"1571_CR10","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","volume":"368","author":"DJ Drucker","year":"2006","unstructured":"Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type\u00a02 diabetes. Lancet. 2006;368(9548):1696\u2013705.","journal-title":"Lancet"},{"issue":"6","key":"1571_CR11","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.it.2008.02.010","volume":"29","author":"K Ohnuma","year":"2008","unstructured":"Ohnuma K, Dang NH, Morimoto C. Revisiting an old acquaintance: CD26 and its molecular mechanisms in T\u00a0cell function. Trends Immunol. 2008;29(6):295\u2013301.","journal-title":"Trends Immunol"},{"key":"1571_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2019.105757","volume":"75","author":"Y Zhao","year":"2019","unstructured":"Zhao Y. CD26 in autoimmune diseases: the other side of \u201cmoonlight protein.\u201d Int Immunopharmacol. 2019;75:105757.","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"1571_CR13","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1177\/10600280211022722","volume":"56","author":"L Sun","year":"2022","unstructured":"Sun L, Wang C, Wu C, Zhou Y, Wang C. Analysis of the clinical characteristics of dipeptidyl peptidase-4 inhibitor-induced bullous pemphigoid. Ann Pharmacother. 2022;56(2):205\u201312.","journal-title":"Ann Pharmacother"},{"issue":"7","key":"1571_CR14","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1111\/ijd.14005","volume":"57","author":"I Garcia-Diez","year":"2018","unstructured":"Garcia-Diez I, Ivars-Lleo M, Lopez-Aventin D, et al. Bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors. Eight cases with clinical and immunological characterization. Int J Dermatol. 2018;57(7):810\u20136.","journal-title":"Int J Dermatol"},{"issue":"2","key":"1571_CR15","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1001\/jamadermatol.2018.4556","volume":"155","author":"SG Lee","year":"2019","unstructured":"Lee SG, Lee HJ, Yoon MS, Kim DH. Association of dipeptidyl peptidase 4 inhibitor use with risk of bullous pemphigoid in patients with diabetes. JAMA Dermatol. 2019;155(2):172\u20137.","journal-title":"JAMA Dermatol"},{"key":"1571_CR16","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.3389\/fimmu.2019.01238","volume":"10","author":"K Tasanen","year":"2019","unstructured":"Tasanen K, Varpuluoma O, Nishie W. Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid. Front Immunol. 2019;10:1238.","journal-title":"Front Immunol"},{"issue":"5","key":"1571_CR17","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1111\/1346-8138.14245","volume":"45","author":"C Chijiwa","year":"2018","unstructured":"Chijiwa C, Takeoka S, Kamata M, et al. Decrease in eosinophils infiltrating into the skin of patients with dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid. J Dermatol. 2018;45(5):596\u20139.","journal-title":"J Dermatol"},{"issue":"4","key":"1571_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13790","volume":"33","author":"K Kridin","year":"2020","unstructured":"Kridin K. Dipeptidyl-peptidase\u00a0IV inhibitors (DPP4i)-associated bullous pemphigoid: estimating the clinical profile and exploring intraclass differences. Dermatol Ther. 2020;33(4):e13790.","journal-title":"Dermatol Ther"},{"key":"1571_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10091916","author":"A Kinyo","year":"2021","unstructured":"Kinyo A, Hanyecz A, Lengyel Z, et al. Clinical, laboratory and histological features of dipeptidyl peptidase-4 inhibitor related noninflammatory bullous pemphigoid. J Clin Med. 2021. https:\/\/doi.org\/10.3390\/jcm10091916.","journal-title":"J Clin Med"},{"issue":"5","key":"1571_CR20","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1684\/ejd.2018.3371","volume":"28","author":"A Patsatsi","year":"2018","unstructured":"Patsatsi A, Kyriakou A, Meltzanidou P, et al. Betaullous pemphigoid in patients with DPP-4 inhibitors at the onset of disease: does this differ from common bullous pemphigoid? Eur J Dermatol. 2018;28(5):711\u20133.","journal-title":"Eur J Dermatol"},{"issue":"2","key":"1571_CR21","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1159\/000527364","volume":"239","author":"E Dandache","year":"2023","unstructured":"Dandache E, Du Thanh A, Girard C, Bessis D, Dereure O. Evolution of bullous pemphigoid clinical pattern over time: a 17-year single-centre retrospective survey of 312 cases. Dermatology. 2023;239(2):235\u201340.","journal-title":"Dermatology"},{"issue":"3","key":"1571_CR22","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s40257-025-00925-z","volume":"26","author":"S Cao","year":"2025","unstructured":"Cao S, Li W, Wang Z, et al. Clinical outcomes and prognostic factors in bullous pemphigoid patients: a 15-year review in China. Am J Clin Dermatol. 2025;26(3):457\u201370.","journal-title":"Am J Clin Dermatol"},{"issue":"9","key":"1571_CR23","doi-asserted-by":"publisher","first-page":"e130","DOI":"10.2337\/dc18-0210","volume":"41","author":"M Arai","year":"2018","unstructured":"Arai M, Shirakawa J, Konishi H, Sagawa N, Terauchi Y. Bullous pemphigoid and dipeptidyl peptidase 4 inhibitors: a disproportionality analysis based on the Japanese Adverse Drug Event Report database. Diabetes Care. 2018;41(9):e130\u20132.","journal-title":"Diabetes Care"},{"issue":"3","key":"1571_CR24","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/jcpt.12397","volume":"41","author":"M Garcia","year":"2016","unstructured":"Garcia M, Aranburu MA, Palacios-Zabalza I, Lertxundi U, Aguirre C. Dipeptidyl peptidase-IV inhibitors induced bullous pemphigoid: a case report and analysis of cases reported in the European pharmacovigilance database. J Clin Pharm Ther. 2016;41(3):368\u201370.","journal-title":"J Clin Pharm Ther"},{"issue":"2","key":"1571_CR25","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/j.1468-3083.2011.04062.x","volume":"26","author":"K Skandalis","year":"2012","unstructured":"Skandalis K, Spirova M, Gaitanis G, Tsartsarakis A, Bassukas ID. Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin. J Eur Acad Dermatol Venereol. 2012;26(2):249\u201353.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"1571_CR26","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1159\/000480498","volume":"233","author":"C Schaffer","year":"2017","unstructured":"Schaffer C, Buclin T, Jornayvaz FR, et al. Use of dipeptidyl-peptidase\u00a0IV inhibitors and bullous pemphigoid. Dermatology. 2017;233(5):401\u20133.","journal-title":"Dermatology"},{"issue":"2","key":"1571_CR27","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1111\/jdi.12695","volume":"9","author":"S Yoshiji","year":"2018","unstructured":"Yoshiji S, Murakami T, Harashima SI, et al. Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors: a report of five cases. J Diabetes Investig. 2018;9(2):445\u20137.","journal-title":"J Diabetes Investig"},{"issue":"10","key":"1571_CR28","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1002\/ccr3.3047","volume":"8","author":"Y Shinohara","year":"2020","unstructured":"Shinohara Y, Iijima T, Sakurai S, et al. Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitor showing unfavorable outcomes despite immediate discontinuation of medication. Clin Case Rep. 2020;8(10):2007\u201312.","journal-title":"Clin Case Rep"},{"issue":"1","key":"1571_CR29","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1186\/s12967-021-03192-8","volume":"19","author":"K Chouchane","year":"2021","unstructured":"Chouchane K, Di Zenzo G, Pitocco D, Calabrese L, De Simone C. Bullous pemphigoid in diabetic patients treated by gliptins: the other side of the coin. J Transl Med. 2021;19(1):520.","journal-title":"J Transl Med"},{"issue":"6","key":"1571_CR30","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1111\/bjd.16479","volume":"178","author":"H Horikawa","year":"2018","unstructured":"Horikawa H, Kurihara Y, Funakoshi T, et al. Unique clinical and serological features of bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors. Br J Dermatol. 2018;178(6):1462\u20133.","journal-title":"Br J Dermatol"},{"issue":"11","key":"1571_CR31","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1016\/j.jid.2016.06.622","volume":"136","author":"K Izumi","year":"2016","unstructured":"Izumi K, Nishie W, Mai Y, et al. Autoantibody profile differentiates between inflammatory and noninflammatory bullous pemphigoid. J Invest Dermatol. 2016;136(11):2201\u201310.","journal-title":"J Invest Dermatol"},{"issue":"11","key":"1571_CR32","volume":"15","author":"H Bodke","year":"2023","unstructured":"Bodke H, Wagh V, Kakar G. Diabetes mellitus and prevalence of other comorbid conditions: a systematic review. Cureus. 2023;15(11):e49374.","journal-title":"Cureus"},{"issue":"6\u20137","key":"1571_CR33","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s10571-009-9368-4","volume":"29","author":"J Benicky","year":"2009","unstructured":"Benicky J, Sanchez-Lemus E, Pavel J, Saavedra JM. Anti-inflammatory effects of angiotensin receptor blockers in the brain and the periphery. Cell Mol Neurobiol. 2009;29(6\u20137):781\u201392.","journal-title":"Cell Mol Neurobiol"},{"key":"1571_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107614","volume":"214","author":"S Dehnavi","year":"2020","unstructured":"Dehnavi S, Sohrabi N, Sadeghi M, et al. Statins and autoimmunity: state-of-the-art. Pharmacol Ther. 2020;214:107614.","journal-title":"Pharmacol Ther"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01571-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01571-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01571-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T09:22:05Z","timestamp":1763198525000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01571-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1571"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01571-3","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"type":"print","value":"2193-8210"},{"type":"electronic","value":"2190-9172"}],"subject":[],"published":{"date-parts":[[2025,10,24]]},"assertion":[{"value":"18 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors Burcu Beksa\u00e7, M. Kaan Temirkaynak, Sheyda Gharehdaghi, Evren Ate\u015fci, G\u00f6zde Kubat, \u00d6zlem Erdem, Nilsel \u0130lter and Esra Ad\u0131\u015fen have no conflict of interest to disclose. Sheyda Gharehdaghi took place in the study as one of the residents in Gazi University, Faculty of Medicine, Department of Dermatology. Since she finished her residency, she is now affiliated with Bazekol Medical Center, Izmir, Turkiye.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study received ethical approval from the Gazi University Faculty of Medicine, Non-Interventional Ethical Committee numbered 431 on May\u00a08, 2023. It was performed in accordance with the Helsinki Declaration of 1964 and its later amendments. No identifiable patient data was presented in this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}